<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036616</url>
  </required_header>
  <id_info>
    <org_study_id>0520/2564</org_study_id>
    <nct_id>NCT05036616</nct_id>
  </id_info>
  <brief_title>Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial</brief_title>
  <official_title>Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation aims to evaluate the filter life time of CRRT membrane and complication of&#xD;
      combining ECMO and CRRT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circuit lifetime</measure>
    <time_frame>72 hours</time_frame>
    <description>The time until a CVVH malfunction was identified</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-Effectiveness</measure>
    <time_frame>72 hours</time_frame>
    <description>To evaluate the cost utility of CRRT between 2 groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>AKI</condition>
  <arm_group>
    <arm_group_label>Separation technique</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Integration technique</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy</intervention_name>
    <description>Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy</description>
    <arm_group_label>Integration technique</arm_group_label>
    <arm_group_label>Separation technique</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients have to be admitted to the ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt; 18 years&#xD;
&#xD;
          2. Refractory acidosis (pH&lt;7.2 or HCO3&lt;15)&#xD;
&#xD;
          3. Refractory volume overload&#xD;
&#xD;
          4. Refractory hyperkalemia (K&gt;6.2mEq/L or EKG change)&#xD;
&#xD;
          5. Anuria or oliguria (urine output &lt;0.5 mL/kg/hr for 6-12hr)&#xD;
&#xD;
          6. High BUN &gt;100 mg/dL or uremic symptom&#xD;
&#xD;
          7. Increase intracranial pressure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Not use heparin in ECMO&#xD;
&#xD;
          3. Chronic kidney disease with CRRT&#xD;
&#xD;
          4. AKI with Glomerulonephritis, Interstitial nephritis, Vassculitis or Urinary tract&#xD;
             obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sasipha tachaboon</last_name>
    <phone>6622564000</phone>
    <phone_ext>3679</phone_ext>
    <email>sasipha_tac@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sasipha tachaboon</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sasipha tachaboon</last_name>
      <email>sasipha_tac@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Nattachai Srisawat ,M.D.</investigator_full_name>
    <investigator_title>Faculty of Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

